PE20151728A1 - 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8 - Google Patents

6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8

Info

Publication number
PE20151728A1
PE20151728A1 PE2015000694A PE2015000694A PE20151728A1 PE 20151728 A1 PE20151728 A1 PE 20151728A1 PE 2015000694 A PE2015000694 A PE 2015000694A PE 2015000694 A PE2015000694 A PE 2015000694A PE 20151728 A1 PE20151728 A1 PE 20151728A1
Authority
PE
Peru
Prior art keywords
tarp
benzothiazol
pyrazol
pyridin
hydroxy
Prior art date
Application number
PE2015000694A
Other languages
English (en)
Spanish (es)
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20151728A1 publication Critical patent/PE20151728A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2015000694A 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8 PE20151728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27

Publications (1)

Publication Number Publication Date
PE20151728A1 true PE20151728A1 (es) 2015-12-02

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000694A PE20151728A1 (es) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8

Country Status (35)

Country Link
US (1) US8765960B2 (enExample)
EP (1) EP2925754B1 (enExample)
JP (1) JP6246227B2 (enExample)
KR (1) KR101693133B1 (enExample)
CN (1) CN104797578B (enExample)
AP (1) AP2015008489A0 (enExample)
AR (1) AR093527A1 (enExample)
AU (1) AU2013352594B2 (enExample)
BR (1) BR112015011200A2 (enExample)
CA (1) CA2889243C (enExample)
CL (1) CL2015001419A1 (enExample)
CR (1) CR20150267A (enExample)
CY (1) CY1118657T1 (enExample)
DK (1) DK2925754T3 (enExample)
DO (1) DOP2015000113A (enExample)
EA (1) EA026686B1 (enExample)
ES (1) ES2618260T3 (enExample)
HR (1) HRP20170274T1 (enExample)
HU (1) HUE033447T2 (enExample)
IL (1) IL238831B (enExample)
JO (1) JO3225B1 (enExample)
MA (1) MA38126B1 (enExample)
MX (1) MX356478B (enExample)
MY (1) MY177721A (enExample)
PE (1) PE20151728A1 (enExample)
PH (1) PH12015501154B1 (enExample)
PL (1) PL2925754T3 (enExample)
PT (1) PT2925754T (enExample)
SG (1) SG11201504164VA (enExample)
SI (1) SI2925754T1 (enExample)
TN (1) TN2015000200A1 (enExample)
TW (2) TW201825484A (enExample)
UA (1) UA114345C2 (enExample)
WO (1) WO2014085153A1 (enExample)
ZA (1) ZA201503733B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
KR20170141767A (ko) * 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 벤즈이미다졸론 및 벤조티아졸론 화합물 및 ampa 수용체 조절제로서의 이들의 용도
BR122023023802A2 (pt) 2015-04-29 2023-12-26 Janssen Pharmaceutica Nv Compostos azabenzimidazóis, seu uso como moduladores do receptor de ampa e composições farmacêuticas que os compreendem
BR112017023200A2 (pt) 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
BR112017023038A2 (pt) 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
JP6953527B2 (ja) * 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ.ベー. 縮合二環ピリジン化合物、及びampa受容体調節因子としてのそれらの使用
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ampa拮抗化合物の新規製造法
WO2001096308A1 (en) * 2000-06-12 2001-12-20 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
JP4988591B2 (ja) * 2004-12-17 2012-08-01 イーライ リリー アンド カンパニー 新規なmch受容体アンタゴニスト
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
US20110178165A1 (en) * 2008-10-08 2011-07-21 Pfizer Inc. Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof
CA2747419C (en) * 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
US8513291B2 (en) * 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US9527807B2 (en) * 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物

Also Published As

Publication number Publication date
ZA201503733B (en) 2017-09-27
KR101693133B1 (ko) 2017-01-04
HRP20170274T1 (hr) 2017-04-07
HK1209116A1 (en) 2016-03-24
DOP2015000113A (es) 2015-06-15
MA38126A1 (fr) 2017-03-31
EA201590823A1 (ru) 2015-08-31
EA026686B1 (ru) 2017-05-31
CA2889243C (en) 2017-06-13
BR112015011200A2 (pt) 2017-07-11
JO3225B1 (ar) 2018-03-08
AP2015008489A0 (en) 2015-05-31
TN2015000200A1 (en) 2016-10-03
IL238831A0 (en) 2015-06-30
IL238831B (en) 2018-08-30
JP6246227B2 (ja) 2017-12-13
CN104797578B (zh) 2016-11-23
SI2925754T1 (sl) 2017-02-28
US20140148441A1 (en) 2014-05-29
TWI618705B (zh) 2018-03-21
MX356478B (es) 2018-05-30
MX2015006697A (es) 2015-08-05
CL2015001419A1 (es) 2015-10-02
AU2013352594A1 (en) 2015-06-04
WO2014085153A1 (en) 2014-06-05
CY1118657T1 (el) 2017-07-12
CR20150267A (es) 2015-09-16
WO2014085153A8 (en) 2014-07-31
ES2618260T3 (es) 2017-06-21
DK2925754T3 (en) 2017-02-20
SG11201504164VA (en) 2015-07-30
KR20150070401A (ko) 2015-06-24
PH12015501154B1 (en) 2018-05-30
CN104797578A (zh) 2015-07-22
EP2925754A1 (en) 2015-10-07
EP2925754B1 (en) 2016-12-28
TW201434834A (zh) 2014-09-16
MA38126B1 (fr) 2017-11-30
TW201825484A (zh) 2018-07-16
CA2889243A1 (en) 2014-06-05
PT2925754T (pt) 2017-02-27
PL2925754T3 (pl) 2017-07-31
AU2013352594B2 (en) 2016-02-18
HUE033447T2 (en) 2017-11-28
AR093527A1 (es) 2015-06-10
UA114345C2 (uk) 2017-05-25
MY177721A (en) 2020-09-23
US8765960B2 (en) 2014-07-01
JP2016501219A (ja) 2016-01-18
PH12015501154A1 (en) 2015-08-10

Similar Documents

Publication Publication Date Title
CR20150370A (es) Compuestos antivirales
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
UY33735A (es) Compuestos antivirales
ECSP11011517A (es) Compuestos antivirales
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
JO3346B1 (ar) مواد مضادة C5aR
CR20150267A (es) 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il] 1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8
EP2925321A4 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
DOP2015000197A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor ¿2 adrenérgico así como actividad antagonista del receptor muscarínico m3.
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
CR20150271A (es) Peptidos como agonistas de oxitocina
PT3044206T (pt) (3z,5s)-5-(hidroximetil)-1-[(2¿-metil-1,1¿-bifenil-4-il)carbonil)pirrolidin-3-ona o-metiloxima como oxitocina/vasopressina via recetores antagonistas para o tratamento de parto prematuro
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
CU20200108A7 (es) Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7
CR20140564A (es) Derivados de pirimidinona como agentes antimaláricos
CO6321288A2 (es) Sales de compuestos inhibidores de vih
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
CR20130196A (es) 1h-pirazol-5-olato sódico sustituido
PE20151003A1 (es) Moduladores alostericos positivos del receptor de acetilcolina nicotinico
CO6321246A2 (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
ECSP14032516A (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales
GT201600004A (es) Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
FG Grant, registration